Compound heterozygous splicing variants expand the genotypic spectrum of EMC1‐related disorders
EMC1 encodes subunit 1 of the endoplasmic reticulum (ER) membrane protein complex (EMC), a transmembrane domain insertase involved in membrane protein biosynthesis. Variants in EMC1 are described as a cause of global developmental delay, hypotonia, cortical visual impairment, and commonly, cerebral...
Saved in:
Published in | Clinical genetics Vol. 103; no. 5; pp. 553 - 559 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 0009-9163 1399-0004 1399-0004 |
DOI | 10.1111/cge.14311 |
Cover
Summary: | EMC1 encodes subunit 1 of the endoplasmic reticulum (ER) membrane protein complex (EMC), a transmembrane domain insertase involved in membrane protein biosynthesis. Variants in EMC1 are described as a cause of global developmental delay, hypotonia, cortical visual impairment, and commonly, cerebral atrophy on MRI scan. We report an individual with severe global developmental delay and progressive cerebellar atrophy in whom exome sequencing identified a heterozygous essential splice‐site variant in intron‐3 of EMC1 (NM_015047.3:c.287‐1G>A). Whole genome sequencing (WGS) identified a deep intronic variant in intron‐20 of EMC1 (NM_015047.3:c.2588‐771C>G) that was poorly predicted by in silico programs to disrupt pre‐mRNA splicing. Reverse Transcription‐PCR (RT‐PCR) revealed stochastic activation of a pseudo‐exon associated with the c.2588‐771C>G variant and mis‐splicing arising from the c.287‐1G>A variant. This case highlights the utility of WGS and RNA studies to identify and assess likely pathogenicity of deep intronic variants and expands the genotypic and phenotypic spectrum of EMC1‐related disorders. |
---|---|
Bibliography: | Funding information Samantha J. Bryen and Katharine Zhang contributed equally to this work. Gina L. O'Grady, Frances J. Evesson, and Sandra T. Cooper contributed equally to this work. Muscular Dystrophy Association; Muscular Dystrophy New South Wales; National Eye Institute; National Health and Medical Research Council; National Heart, Lung, and Blood Institute, Grant/Award Number: UM1 HG008900; National Human Genome Research Institute, Grant/Award Number: R01 HG009141; National Institutes of Health, Grant/Award Numbers: R01 HL093093, R01 HL133040, TOPMed program (R01 HL117626 02S1), U01 HL120393; contract HHSN268201800001I, contract HHSN268201800002I R01 HL120393 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 R.L.M: Soifua Manuia study analysis of genomic data T.N. M.S.R, S.V: Soifua Manuia study conceptualization, participant recruitment L.B.W: Ethics, analysis of genomic data, manuscript editing Author Contribution Statement S.B: RNA studies F.J.E: Project oversight and supervision, CRISPR/Cas9 gene editing, manuscript editing G.L.O: Clinical data and management of family, analysis of genomic data, manuscript preparation S.J.B: Genomic analyses, RNA studies, manuscript and figure preparation G.D: Western blot These authors contributed equally to this work A.C: Skeletal muscle histopathology S.T.C: Project oversight and supervision, analysis, manuscript editing K.Z: Western blot, RNA studies, CRISPR/Cas9 gene editing, manuscript and figure preparation |
ISSN: | 0009-9163 1399-0004 1399-0004 |
DOI: | 10.1111/cge.14311 |